Researchers at Saint Louis University in Missouri plan to tackle the twin epidemics of diabetes and obesity by tapping into the potential of two nuclear receptors that control muscle metabolism. The scientists are working to optimize two promising drug compounds, moving a step closer toward capturing the benefits of exercise in pill form.

A new study conducted at the Johns Hopkins Kimmel Cancer Center has provided evidence that random and unpredictable DNA copying “mistakes” account for nearly two-thirds of the mutations that cause cancer.

Researchers from Emory University have found that specific patterns of activity on brain scans may help clinicians identify whether psychotherapy or antidepressant medication is more likely to help individual patients recover from depression.

Developing new treatments for diseases often requires large numbers of clinical research participants enrolled in the same study at numerous geographical sites.

The FDA has approved avelumab injection (intravenous) 20 mg/mL (Bavencio, EMD Serono) for the treatment of adults and pediatric patients 12 years of age and older with metastatic Merkel cell carcinoma (mMCC).

President Trump turned his push for the American Health Care Act in a zero-sum game: Either the House passes the AHCA today or Obamacare stays, the Wall Street Journal reports. Trump is done negotiating, White House Budget Director Mick Mulvaney told wavering House members last night.

A group of doctors at Eastern Virginia Medical School in Norfolk, Virginia, has reported remarkable success in treating sepsis patients who were at high risk of sudden death, according to an article posted on the National Public Radio (NPR) website.

Pointing to a lack of financial resources and qualified information technology (IT) professionals, 64% of health care providers said they were not prepared to meet reporting requirements under the Medicare Access and Children’s Health Insurance Program Reauthorization Act (MACRA), according to a new survey.

Given earlier impressive clinical trial results, investors expect the FDA to clear both Roche’s multiple sclerosis (MS) treatment ocrelizumab (Ocrevus) and Sanofi’s new eczema drug dupilumab (Dupixent), according to a Reuters report.

Acting on a request from three influential senators, the Government Accountability Office (GAO) has confirmed that it will investigate potential abuses of the Orphan Drug Act (ODA), according to a report from Kaiser Health News (KHN). The GAO is expected to begin its work in about nine months.

The uncertainty surrounding the Republican effort to replace the Patient Protection and Affordable Care Act (PPACA) is forcing some hospitals to delay expansion plans, cut costs, or take on added risk to borrow money for capital investment projects, according to a Reuters report.

When Harvard Pilgrim Health Care recently unveiled value-based contracts for two expensive medications, etanercept (Enbrel) and teriparatide (Forteo), the news caused a stir

Nearly all patients who completed at least eight weeks of hepatitis C treatment with Harvoni (ledipasvir/sofosbuvir, Gilead Sciences) were cured of the disease, according to a new study conducted by pharmacy benefit manager Prime Therapeutics. Prime will present the data next week at the Academy of Managed Care Pharmacy’s 2017 annual meeting.

Disappointing results have been reported from a global phase 3 trial investigating the efficacy, safety, and tolerability of serelaxin (Novartis) in patients with acute heart failure (AHF).

The FDA has greenlighted safinamide (Xadago, Newron Pharmaceuticals), a selective monoamine oxidase B inhibitor, as an add-on treatment for patients with Parkinson’s disease (PD) who experience “off” episodes while receiving levodopa/carbidopa.

Pages